Oxycodone/naloxone

Oxycodone/naloxone
Combination of
Oxycodone Opioid analgesic
Naloxone Opioid receptor antagonist
Clinical data
AHFS/Drugs.com International Drug Names
UK Drug Information
Pregnancy
category
  • C
Routes of
administration		 Oral
ATC code N02AA55 (WHO)
Legal status
Legal status
Identifiers
  (verify)

Oxycodone/naloxone is a combination analgesic drug available as modified-release tablets under the trade names Targin (produced by Mundipharma), Targiniq and Targinact.

The oxycodone component is an opioid and is responsible for the pain-relieving effects. Naloxone opposes the effects of opioids but is poorly absorbed into the body when given orally, meaning almost all the dose stays within the gastrointestinal tract and reduces the local side effects from the oxycodone. Constipation was significantly relieved in a 2008 study.[1] The drug was released in 2006 in Germany and is available in some other European countries since 2009.[2]

Adverse effects

Further information: Oxycodone § Adverse effects

If the drug is used off license by crushing the tablet and dissolving it for injection, it may precipitate severe opiate withdrawal symptoms due to the much higher bioavailability of intravenous naloxone compared to oral naloxone. In simpler terms, since naloxone is an opioid antagonist, it will bind to the opioid receptors in the brain and block the analgesic effect of the oxycodone.

See also

References

  1. ↑ Simpson K, et al. (December 2008). "Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain". Curr Med Res Opin. 24 (12): 3503–3512. doi:10.1185/03007990802584454. PMID 19032132. Retrieved 2009-04-09.
  2. ↑ Mundipharma (2009-01-26). "Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation". Retrieved 2009-04-09.



This article is issued from Wikipedia - version of the 8/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.